The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Background. Attention to the administration of probiotics for the treatment of psoriasis has recently increased. Aim. In the present study, improvements in dermatology life quality index (DLQI), psoriasis area severity index (PASI), and visual analogue scale (VAS) scores in the psoriasis patients re...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/4549134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850234481925947392 |
|---|---|
| author | Ali Akbarzadeh Pedram Alirezaei Amin Doosti-Irani Maryam Mehrpooya Fatemeh Nouri |
| author_facet | Ali Akbarzadeh Pedram Alirezaei Amin Doosti-Irani Maryam Mehrpooya Fatemeh Nouri |
| author_sort | Ali Akbarzadeh |
| collection | DOAJ |
| description | Background. Attention to the administration of probiotics for the treatment of psoriasis has recently increased. Aim. In the present study, improvements in dermatology life quality index (DLQI), psoriasis area severity index (PASI), and visual analogue scale (VAS) scores in the psoriasis patients receiving Lactocare® probiotic were compared to psoriasis patients receiving placebo. Methods. A total of 52 psoriasis patients were included in this study and randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone associated with placebo; in the treatment group, Lactocare® was administrated orally associated with hydrocortisone. The mean of VAS, DLQI, and PSAI scores was recorded and evaluated pretreatment and post-treatment in both groups for 3 months. The mean of the scores in the control groups was compared to the treatment group. Intragroup analysis was preformed with a comparison of the mean of these scores at baseline 4-, 8-, and 12-weeks post-treatment. Results. In the treatment group, a significant decrease was seen in PASI, VAS, and DLQI scores compared to the control group on week 12 post-treatment. Conclusion. Oral administration of Lactocare® probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment. PASI reduction occurred in all patients who received probiotics. |
| format | Article |
| id | doaj-art-1693269b02fa4a6fb75cae56794c4292 |
| institution | OA Journals |
| issn | 1687-6113 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-1693269b02fa4a6fb75cae56794c42922025-08-20T02:02:37ZengWileyDermatology Research and Practice1687-61132022-01-01202210.1155/2022/4549134The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAli Akbarzadeh0Pedram Alirezaei1Amin Doosti-Irani2Maryam Mehrpooya3Fatemeh Nouri4Department of Pharmaceutical BiotechnologyPsoriasis Research CenterDepartment of EpidemiologyDepartment of Clinical PharmacyDepartment of Pharmaceutical BiotechnologyBackground. Attention to the administration of probiotics for the treatment of psoriasis has recently increased. Aim. In the present study, improvements in dermatology life quality index (DLQI), psoriasis area severity index (PASI), and visual analogue scale (VAS) scores in the psoriasis patients receiving Lactocare® probiotic were compared to psoriasis patients receiving placebo. Methods. A total of 52 psoriasis patients were included in this study and randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone associated with placebo; in the treatment group, Lactocare® was administrated orally associated with hydrocortisone. The mean of VAS, DLQI, and PSAI scores was recorded and evaluated pretreatment and post-treatment in both groups for 3 months. The mean of the scores in the control groups was compared to the treatment group. Intragroup analysis was preformed with a comparison of the mean of these scores at baseline 4-, 8-, and 12-weeks post-treatment. Results. In the treatment group, a significant decrease was seen in PASI, VAS, and DLQI scores compared to the control group on week 12 post-treatment. Conclusion. Oral administration of Lactocare® probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment. PASI reduction occurred in all patients who received probiotics.http://dx.doi.org/10.1155/2022/4549134 |
| spellingShingle | Ali Akbarzadeh Pedram Alirezaei Amin Doosti-Irani Maryam Mehrpooya Fatemeh Nouri The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Dermatology Research and Practice |
| title | The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| title_full | The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| title_fullStr | The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| title_full_unstemmed | The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| title_short | The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| title_sort | efficacy of lactocare r synbiotic on the clinical symptoms in patients with psoriasis a randomized double blind placebo controlled clinical trial |
| url | http://dx.doi.org/10.1155/2022/4549134 |
| work_keys_str_mv | AT aliakbarzadeh theefficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT pedramalirezaei theefficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT amindoostiirani theefficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT maryammehrpooya theefficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT fatemehnouri theefficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT aliakbarzadeh efficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT pedramalirezaei efficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT amindoostiirani efficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT maryammehrpooya efficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial AT fatemehnouri efficacyoflactocaresynbioticontheclinicalsymptomsinpatientswithpsoriasisarandomizeddoubleblindplacebocontrolledclinicaltrial |